RRM1 and cholangiocarcinoma: RRM1 positivity (RRM1 negativity has been associated with gemcitabine response34) was associated with PD‐L1 expression in nonepithelial ovarian cancer (p = 0.025), soft tissue sarcoma (p = 0.010), pancreatic cancer (p = 0.032), female genital tract malignancy (p = 0.016) and cholangiocarcinoma (p = 0.002).